Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly has announced a new open innovation challenge aimed at enhancing care for individuals with atopic dermatitis. The challenge invites submissions for digital health solutions that improve quality of life for patients dealing with this chronic skin condition. Entries will be accepted until October 21, 2020, with five finalists selected by November 20, 2020. The winning submission will receive a $50,000 award and a potential collaboration opportunity with Lilly. This initiative aligns with Lilly's commitment to leveraging technology for better health outcomes.
The FDA has granted Fast Track designation to Jardiance (empagliflozin) for preventing hospitalization and mortality in patients post-heart attack. Approximately 1.5 million heart attacks annually contribute significantly to heart failure risks. The EMPACT-MI trial aims to evaluate Jardiance's effectiveness in improving survival rates. Jardiance is already approved for lowering blood sugar in type 2 diabetes patients and reducing cardiovascular death risk. Results from the EMPACT-MI trial are anticipated in 2023, marking a critical advance in patient care.
Eli Lilly and Incyte announced promising results from the Adaptive COVID-19 Treatment Trial (ACTT-2), which involved over 1,000 hospitalized patients. The trial assessed the efficacy of baricitinib combined with remdesivir, showing a significant reduction of approximately one day in median recovery time compared to remdesivir alone. This finding is statistically significant and meets the primary endpoint of the study. Lilly intends to seek emergency use authorization for the 4-mg dose of baricitinib for COVID-19 treatment, while also continuing trials to understand its full potential.
Innovent Biologics and Eli Lilly announced the presentation of six clinical studies on TYVYT® (sintilimab injection) at the ESMO Virtual Congress 2020 from September 19-21. The studies cover various cancers, including lung, gynecological, hepatocellular, and gastric cancers. Significant findings include the ORIENT-11 and ORIENT-12 studies demonstrating the efficacy of sintilimab in combination therapies for advanced lung cancer. These presentations aim to enhance understanding of the drug's efficacy and guide future treatments.
Innovent and Eli Lilly announce the presentation of six clinical studies for TYVYT® (sintilimab injection) at the upcoming ESMO Virtual Congress 2020 from September 19-21. Key studies include Phase 3 trials for lung cancer and hepatocellular carcinoma, showing positive preliminary efficacy. Innovations include the combination of sintilimab with various chemotherapy agents, providing insights into patient selection and treatment outcomes. The collaboration between Innovent and Lilly emphasizes a strong partnership in advancing oncology treatments.
Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020. Joshua Smiley, the Chief Financial Officer, will engage in a virtual fireside chat at 8:40 a.m. Eastern Time. A live audio webcast will be available on Lilly's Investor website, with a replay accessible for 90 days post-event. Lilly, a leading healthcare company, is committed to discovering and creating medicines that improve lives worldwide.
Eli Lilly will participate in the Morgan Stanley Global Healthcare Conference on September 16, 2020. Joshua Smiley, CFO, will engage in a virtual fireside chat at 3:30 p.m. ET. A live audio webcast will be accessible on Lilly's Investor website, alongside a replay available for 90 days.
Lilly, a global healthcare leader, focuses on developing life-changing medicines and enhancing disease understanding. For more details, visit www.lilly.com.
Eli Lilly's recent Phase 3 CENTURION study reveals that REYVOW™ (lasmiditan) significantly improves pain freedom in adults suffering from migraines. Results show participants taking REYVOW at 200 mg experienced 4.6 times greater odds of pain freedom at 2 hours compared to placebo, while those at 100 mg had 3.8 times greater odds. Additionally, REYVOW demonstrated differences in pain relief and sustained freedom from pain up to 48 hours. Safety findings align with earlier studies, confirming a tolerable profile.
Eli Lilly will conduct a webcast on September 21, 2020, at 3:00 PM EDT, to discuss its presentations at the 2020 ESMO Virtual Congress. Investors, media, and the public can access the live webcast via a link on Lilly's website. A replay will be available afterwards. Lilly is committed to discovering and delivering life-changing medicines to improve health outcomes globally.
Eli Lilly and Company (NYSE: LLY) has expanded its Lilly Insulin Value Program, introducing a $35 copay card to help individuals with diabetes manage their insulin costs. This program, effective from January 2021, is aimed at people with commercial insurance and the uninsured, alleviating financial burdens associated with insulin purchases. Lilly also noted the integration of this copay card into their broader affordability solutions, which support approximately 20,000 patients monthly. Lilly's initiatives include partnerships to raise awareness about insulin affordability and options available to patients.